16:45 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest inhibiting activity in the primary somatosensory cortex (S1DZ) in offspring could treat social and behavioral abnormalities caused by virus-induced maternal immune activation (MIA) during pregnancy. In offspring from a mouse...
07:00 , Apr 15, 2013 |  BioCentury  |  Product Development

Gene therapy in sight

Gene therapy has been more or less off the radar for years, but last week's big series A round for GenSight Biologics Inc. reflects the investors' confidence that gene therapies for the eye can be...
08:00 , Nov 22, 2010 |  BioCentury  |  Emerging Company Profile

Apexigen: rAbbits Hop Rodents

Looking to exploit antibody generation processes unique to a rabbit's immune system, Apexigen Inc. is developing humanized mAbs that it believes will have best-in-class potential by offering better affinity and specificity than humanized murine antibodies....
07:00 , Jul 19, 2010 |  BioCentury  |  Emerging Company Profile

Eos Neuroscience: Lighting the way

When photoreceptor cells die, the retina is no longer sensitive to light even though retinal cells downstream in the phototransduction cascade remain intact. Eos Neuroscience Inc. is developing a gene therapy to make a specific...
07:00 , Jul 15, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinitis Halorhodopsin In vitro, ex vivo and mouse studies suggest that Natronomonas pharaonis halorhodopsin gene therapy could help treat retinitis pigmentosa, a disease characterized...
07:00 , May 14, 2009 |  BC Innovations  |  Cover Story

Beating the brain's bouncer

Three research teams have developed new insights into the structure and function of the chief gatekeeper at the blood brain barrier-a multipurpose small molecule transporter called P-glycoprotein. The transporter has long been a bugbear to...
07:00 , Sep 10, 2007 |  BioCentury  |  Tools & Techniques

Metabasis' quantum hop

The pharmaceutical industry rarely uses free energy perturbation-based methods in computer-aided drug design because these methods have low throughput, require a high level of user expertise and do not always produce results of the desired...